Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis

Tanaka, Marenao; Yamashita, Tomohisa; Koyama, Masayuki; Moniwa, Norihito; Ohno, Kohei; Mitsumata, Kaneto; Itoh, Takahito; Furuhashi, Masato; Ohnishi, Hirofumi; Yoshida, Hiroyuki; Tsuchihashi, Kazufumi; Miura, Tetsuji; Investigators, Boreas Hd study

doi:10.1007/s10157-015-1182-3

Cited by 5 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 3 ] Recently, studies show that mortality and hospitalization rate of CKD patients can be reduced by use of statins and angiotensin II receptor antagonists. [ 4 , 5 ]…”

Section: Introductionmentioning

confidence: 99%

The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis

Ren²,

Han³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…[ 3 ] Recently, studies show that mortality and hospitalization rate of CKD patients can be reduced by use of statins and angiotensin II receptor antagonists. [ 4 , 5 ]…”

Section: Introductionmentioning

confidence: 99%

The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis

Ren²,

Han³

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…Antihipertansif ilaçlarla hemodiyalize giren hastalardaki mortalite ilișkisini değerlendirmek amacıyla çeșitli çalıșmalar yapılmıștır. hemodiyalize giren hastalarda beta bloker, ARB ve kalsiyum kanal blokeri kullanımının mortaliteyi azalttığı değișik çalıșmalarda saptanmıștır (19)(20)(21).…”

Section: Bulgularunclassified

Hemodiyaliz Hastalarında Mortaliteye Etkisi Olan Kan Parametreleri ve Ekokardiyografi Bulguları

Alanlı

Küçükay

MÜRSEL

et al. 2022

Ankara Eğitim Ve Araştırma Hastanesi Tıp Dergisi

View full text Add to dashboard Cite

Aim: To determine demographic characteristics, concomitant diseases, relationships between mortality and laboratory test parameters and echocardiography findings. Material and Method: Between July 2017 and July 2021, 755 patients who were undergoing hemodialysis because of chronic kidney disease regularly were inspected retrospectively. Patients under 18 years of age and patients who were undergoing hemodialysis for less than two months were excluded. Results: Age over 65 years, increased levels of C-reactive protein, ferritin, red cell diameter width, alkaline phosphatase, and decreased levels of albumin, calcium, total protein and low ejection fraction (EF) in echocardiography were found to have significant relationships. There were correlation between mortality and age, albumin levels, existence of hypertension, hyperlipidemia and low EF values. Conclusion: Advanced age, low albumin levels and low EF values and existence of hyperlipidemia and hypertension result in increased risk of mortality in hemodialysis patients. These patients must be carefully monitored. Anti-hypertensive medications have protective effects, and must be preferred whenever possible in hemodialysis patients.

show abstract

“…All patients on HD in 22 institutes affiliated with Sapporo Medical University in the first week of January 2009 (n = 1, 071) were initially enrolled in the BOREAS HD registry [11]. Prespecified exclusion criteria were transient HD and history of kidney transplantation.…”

Section: Methodsmentioning

confidence: 99%

“…However, there have been only a few studies in which relationships between the number of anti-thrombosis (AP and/or anti-coagulant) agents, clinical benefits and adverse events including major hemorrhage were examined [9, 10]. Thus, in the present study, we analyzed data in a registry for a cohort for patients on HD (n = 1, 071), BOREAS-HD Registry [11], to clarify the relationships between mortality, ischemic events, hemorrhagic events and number of anti-thrombosis agents in HD patients.…”

Section: Introductionmentioning

confidence: 99%

Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study

Tanaka

Moniwa

Ohnishi

et al. 2017

Kidney Blood Press Res

Self Cite

View full text Add to dashboard Cite

Background/Aims: Relationships between the number of anti-thrombosis agents, clinical benefits and adverse events in hemodialysis (HD) patients are unclear. Methods: All patients on HD in 22 institutes (n = 1,071) were enrolled and followed up for 3 years. After exclusion of patients with missing data, kidney transplantation or retraction of consent during the follow-up period (n = 204), mortality rate and ischemic and hemorrhagic events were compared between different regimens of anti-thrombosis agents. Results: The use of dual or triple antiplatelet (AP) agents (HR:2.03, 95% CI:1.01-4.13, p = 0.04) and the combination of an AP agent and warfarin (WF) (HR:4.84, 95%CI 1.96-11.96, p < 0.001) were associated with an increase in hemorrhagic events compared with no use of anti-thrombosis agents. No anti-thrombosis regimen was associated with a significant change in risk of ischemic stroke. The use of dual or triple AP agents, but not WF, was associated with an increase in cardiovascular mortality (HR:2.48, 95% CI:1.24-4.76, p = 0.01). Conclusion: A significant increase in hemorrhagic events by the use of dual or more AP agents and by co-administration of an AP agent and WF in patients on HD should be considered in planning their anti-thrombosis regimen.

show abstract

Impact of use of angiotensin II receptor blocker on all-cause mortality in hemodialysis patients: prospective cohort study using a propensity-score analysis

Abstract: The use of an ARB, but not a CCB, is associated with reduced all-cause and cardiovascular mortalities in patients on HD.

Cited by 5 publications

References 27 publications

The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis

The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis

Hemodiyaliz Hastalarında Mortaliteye Etkisi Olan Kan Parametreleri ve Ekokardiyografi Bulguları

Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study

Contact Info

Product

Resources

About